greeksoup/ stock research
Stock research / United States / SYK · Surgical & Medical Instruments & Apparatus · NYSE

Stryker Corp. (SYK)

Stryker makes medical technology: surgical equipment and navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, intensive care disposables, products for brain and skull-based surgery, minimally invasive products for stroke and venous thromboembolism, implants used in joint replacement and trauma surgery, and Mako robotic-arm assisted technology. Most of it is marketed directly to doctors, hospitals and other healthcare facilities. The company was incorporated in Michigan in 1946 as successor to a business founded in 1941 by Dr. Homer H. Stryker, an orthopaedic surgeon and inventor of medical devices. It reports two segments: MedSurg and Neurotechnology, which was 62% of net sales in 2025, and Orthopaedics, 38%.

Stryker Corp.

Stryker makes medical technology: surgical equipment and navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, intensive care disposables, products for brain and skull-based surgery, minimally invasive products for stroke and venous thromboembolism, implants used in joint replacement and trauma surgery, and Mako robotic-arm assisted technology. Most of it is marketed directly to doctors, hospitals and other healthcare facilities. The company was incorporated in Michigan in 1946 as successor to a business founded in 1941 by Dr. Homer H. Stryker, an orthopaedic surgeon and inventor of medical devices. It reports two segments: MedSurg and Neurotechnology, which was 62% of net sales in 2025, and Orthopaedics, 38%.

MedSurg and Neurotechnology

Five businesses sit inside it. Medical, the largest at 27% of the segment's 2025 sales, covers patient handling, emergency medical equipment, intensive care disposables, clinical communication and an artificial intelligence-assisted virtual care platform. Endoscopy, 24%, covers endoscopic and communications systems. Instruments, 20%, covers surgical equipment, patient and caregiver safety technologies and navigation systems. Neuro Cranial, 16%, covers products for traditional brain and open skull-based surgical procedures plus orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation. Vascular, 13%, covers minimally invasive products for acute ischemic and hemorrhagic stroke and for venous thromboembolism.

Vascular was called Neurovascular until the 2025 acquisition of Inari Medical, whose portfolio treats venous thromboembolism, and the two were put together under the new name. It launched the Broadway System in the United States, an integrated stroke solution for large- and super-bore catheter procedures, and accelerated the launch of the Surpass Elite Flow Diverting Stent in the United States, Europe and parts of Asia-Pacific, designed to reduce thrombin generation compared with unmodified stents. Neuro Cranial launched OptaBlate BVN, a radiofrequency nerve ablation system used to reach and ablate the basivertebral nerve to treat vertebrogenic pain. Medical completed the acquisition of Advanced Medical Balloons, an indwelling fecal management system built on ultra-thin polyurethane, which the company adds to its Sage incontinence portfolio.

Orthopaedics

Implants used in total joint replacement of the hip, knee, shoulder and ankle, and in trauma and extremities surgery, together with the instrumentation that goes with them. In 2025, trauma and extremities was 42% of the segment's sales, knees 28%, hips 20%, other 9% and spinal implants 2%, the last down from 8% in 2024.

Mako

The robotic platform runs through the orthopaedic business and is now available in more than 45 countries. The company reports that over one million robotic Mako Total Knee procedures, and more than two million robotic procedures across Mako Total Knee, Mako Total Hip and Mako Partial Knee, have been performed worldwide to date. In 2025 it introduced the Mako 4 platform.

Who it competes with

The filing names its competitors business by business. In Instruments it lists Zimmer Biomet, Medtronic, Johnson & Johnson MedTech and ConMed Linvatec. In Endoscopy, Karl Storz, Olympus Optical, Smith & Nephew, ConMed Linvatec, Arthrex and STERIS. In Medical, Baxter International, Zoll Medical, Medline Industries and Ferno-Washington. In Vascular and Neuro Cranial, Medtronic and Johnson & Johnson among others. In joint replacement, trauma and extremities and robotics, Zimmer, Johnson & Johnson MedTech and Smith & Nephew.

From Stryker's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Stryker became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 30 October 2026
Revenue
$6.5 billion
+7.6% on the year · -1.0% on the quarter
Q4 FY2024Q3 FY2026
Net income
$753 million
-12.3% on the year · -41.0% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$1.96
-11.7% on the year · -40.6% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 11 February 2026
Revenue
$25.1 billion
+11.2% on the year
FY2018FY2025
Net income
$3.2 billion
+8.5% on the year
FY2018FY2025
Diluted EPS
$8.40
+8.2% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsStryker (SYK) reported revenue of $25.1 billion for fiscal 2025, the year ended 31 December 2025, up 11.2% on the year before. Net income was $3.2 billion and diluted earnings per share $8.40. Revenue was $22.6 billion in fiscal 2024, $20.5 billion in fiscal 2023, $18.4 billion in fiscal 2022 and $17.1 billion in fiscal 2021. Net income in the same years was $3.0 billion, $3.2 billion, $2.4 billion and $2.0 billion. Over the twelve months to 30 September 2026, Stryker reported revenue of $26.3 billion and net income of $3.6 billion. Revenue grew 11.8% a year, compounded, over the five years to fiscal 2025. Stryker declared $3.52 a share in dividends over the last four quarters and had 381 million shares outstanding at the latest filed count. At 30 September 2026 it carried $14.9 billion of debt and $3.3 billion of cash. At the close of 6 November 2026 the market cap of Stryker was $124.0 billion, 34.7 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE15.4%
ROCE14.2%
Operating margin20.7%
Net margin13.8%
FCF margin17.4%
Interest cover9.3x
Debt to equity0.64x
Cash conversion1.50x
Share count, last 12 months-0.5%
Sales CAGR, 3 years10.8%
Profit CAGR, 3 years11.2%
EPS, TTM$9.39

At the close of 6 November 2026

Price$325.82
Market cap$124.0 billion
Stock P/E34.7x
Price to book5.3x
EV / EBITDA19.3x
Dividend yield1.1%
Market cap / sales4.7x
52-week high$387.46
52-week low$269.75
Price, 1 year-7.9%
Price CAGR, 3 years5.8%
Price CAGR, 5 years3.4%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the total debt Stryker Corp. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
SYKgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022Q1 FY2023Q2 FY2023Q3 FY2023 †Q4 FY2023Q1 FY2024Q2 FY2024 †Q3 FY2024Q4 FY2024 †Q1 FY2025Q2 FY2025 †Q3 FY2025 †Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue4,7014,2754,4934,4795,2024,7784,9964,9095,8155,2435,4225,4946,4365,8666,0226,0577,1716,0206,5896,520
Cost of revenue1,6561,5411,6671,6971,9661,7621,8151,7512,1121,9102,0061,9772,2622,1222,1812,2052,5432,2102,0912,272
Gross profit3,0452,7342,8262,7823,2363,0163,1813,1583,7033,3333,4163,5174,1743,7443,8413,8524,6283,8104,4984,248
Gross margin65%64%63%62%62%63%64%64%64%64%63%64%65%64%64%64%65%63%68%65%
R&D331413351364326339346353350368363377358405407410401413434433
SG&A1,7451,7101,5391,4551,7511,7811,7061,7101,9411,8401,8311,8962,1182,3002,0792,0452,2272,2812,2292,313
Operating income8194477728088147359659311,2579721,0511,0855818371,1131,1351,8049361,6591,034
Operating margin17%10%17%18%16%15%19%19%22%19%19%20%9%14%18%19%25%16%25%16%
Interest expensen/an/an/an/an/an/an/an/an/an/a96.098.0n/a137159157154148141143
Pre-tax income7573867208167616798998691,2269239981,0435287641,0161,0291,7058501,564997
Tax rate13%16%9%0%26%13%18%20%7%15%17%20%-3%14%13%17%50%12%18%24%
Net income6623236568165635927386921,1437888258345466548848598497451,276753
Net margin14%8%15%18%11%12%15%14%20%15%15%15%8%11%15%14%12%12%19%12%
Diluted EPS$1.73$0.84$1.72$2.14$1.47$1.54$1.93$1.80$2.98$2.05$2.14$2.16$1.41$1.69$2.29$2.22$2.20$1.93$3.30$1.96
Operating cash flow1,0002035298891,0034456881,0501,5282046331,4741,9312501,1111,5402,1435811,2611,461
Capital expenditure206119143138188130152148145167152170266123183187268166202237
Free cash flow79484.03867518153155369021,38337.04811,3041,6651279281,3531,8754151,0591,224
Dividends paid237262263263263284285285285304305305305320321322321337337338
Shares outstanding378m378m378m378m379m380m380m380m380m381m381m381m382m382m382m382m383m383m384m381m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read moreA quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020FY2021FY2022 †FY2023 †FY2024FY2025TTM
Revenue6,0006,7186,7237,3208,3078,6579,0219,6759,94611,32512,44413,60114,88414,35117,10818,44920,49822,59525,11626,300
Cost of revenue1,8652,1312,1842,2862,8112,7813,0023,3193,3443,8214,2644,6635,1885,2946,1406,8717,4408,1559,0519,116
Gross profit4,1354,5874,5395,0345,4965,8766,0196,3566,6027,4958,1738,9389,6969,05710,96811,57813,05814,44016,06517,184
Gross margin68.9%68.3%67.5%68.8%66.2%67.9%66.7%65.7%66.4%66.2%65.7%65.7%65.1%63.1%64.1%62.8%63.7%63.9%64.0%65.3%
Research and development3753683363944624715366146257157878629719841,2351,4541,3881,4661,6231,681
Selling, general and administrative2,3922,6252,5062,7073,1503,3673,4673,5473,6104,1374,5525,0995,3565,3616,4276,3867,1117,6858,6519,050
Operating income1,3071,5191,5941,7511,6861,7411,2561,2461,8612,1752,2972,5372,7132,2232,5842,8413,8883,6894,8895,433
Operating margin21.8%22.6%23.7%23.9%20.3%20.1%13.9%12.9%18.7%19.2%18.5%18.7%18.2%15.5%15.1%15.4%19.0%16.3%19.5%20.7%
Interest expensen/a12.714.053.056.063.083.0113108228247264287315337337363409607586
Pre-tax income1,3701,5801,6241,7301,6861,7051,2121,1601,7351,9212,0632,3562,5621,9542,2812,6833,6733,4924,5145,116
Income tax3834325164563414072066452962741,043-1,1974793552873255084991,2681,493
Effective tax rate28.0%27.4%31.8%26.4%20.2%23.9%17.0%55.6%17.1%14.3%50.6%-50.8%18.7%18.2%12.6%12.1%13.8%14.3%28.1%29.2%
Net income1,0171,1481,1071,2731,3451,2981,0065151,4391,6471,0203,5532,0831,5991,9942,3583,1652,9933,2463,623
Net margin17.0%17.1%16.5%17.4%16.2%15.0%11.2%5.3%14.5%14.5%8.2%26.1%14.0%11.1%11.7%12.8%15.4%13.2%12.9%13.8%
Diluted EPS$2.44$2.78$2.77$3.19$3.45$3.39$2.63$1.34$3.78$4.35$2.68$9.34$5.48$4.20$5.21$6.17$8.25$7.76$8.40$9.39
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2009 to FY2025

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
MedSurg and Neurotechnologyn/an/an/an/an/an/an/an/an/an/a8,4758,3459,53810,61111,83613,51815,64762.3%
Orthopaedics3,3843,5493,7103,8233,9494,1534,2234,4224,7134,9916,4096,0067,5707,8388,6629,0779,46937.7%
MedSurg2,4272,8033,1603,2653,4143,7813,8954,8945,5576,045n/an/an/an/an/an/an/an/a
Neurotechnology and Spine9129681,4371,5691,6581,7411,8282,0092,1742,565n/an/an/an/an/an/an/an/a
MedSurg and Neurotechnology FY2019 to FY2025OrthopaedicsMedSurg FY2009 to FY2018Neurotechnology and Spine FY2009 to FY2018
7.3FY20109.0FY201311.3FY201614.9FY201918.4FY202225.1FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Profit by segment FY2014 to FY2025

The operating profit each segment reports. Costs Stryker does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Margin
FY2025
MedSurg and Neurotechnologyn/an/an/an/an/a2,3042,4142,8072,8313,4704,0044,67229.9%
Orthopaedics1,4101,4871,6021,6811,8042,0841,5882,1802,2022,2652,5912,82029.8%
MedSurg8508221,0871,2281,444n/an/an/an/an/an/an/an/a
Neurotechnology and Spine476474559631700n/an/an/an/an/an/an/an/a
MedSurg and Neurotechnology FY2019 to FY2025MedSurg FY2014 to FY2018OrthopaedicsNeurotechnology and Spine FY2014 to FY2018
2,783FY20153,540FY20174,388FY20194,987FY20215,735FY20237,492FY2025

$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2025Share of salesShare of profit
MedSurg and Neurotechnology62%62%
Orthopaedics38%38%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by region FY2012 to FY2025

FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States5,6585,9846,5587,1168,2309,0599,84810,95710,45512,32113,63815,25716,94319,00675.7%
Europe, Middle East, Africa1,2661,3161,3711,2671,4371,5671,7931,8881,8182,2992,3482,6182,8973,18112.7%
Asia Pacific1,3361,3191,3681,2511,3251,4131,5321,6171,6301,9731,8851,9462,0202,1648.6%
Other foreign countries3974023783123334054284224485155786777357653.0%
United StatesEurope, Middle East, AfricaAsia PacificOther foreign countries
9.0FY20139.9FY201512.4FY201714.9FY201917.1FY202120.5FY202325.1FY2025

$ billion; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Stryker's adjusted EPS landed at or above the top of the range in 3, inside it in 2 and under it in 4 of the 9 years shown (FY2012 to FY2025).

+8.8%FY2012−3.9%FY2013−3.5%FY2014−19.2%FY2020−1.2%FY2021−6.6%FY2022+4.4%FY2023+1.6%FY2024−0.5%FY2025
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.

Fiscal yearFirst forecast
adjusted EPS		Result
FY2012$3.72 to $3.74$4.07
FY2013$4.25 to $4.40$4.23
FY2014$4.75 to $4.90$4.73
FY2020$9.00 to $9.20$7.43
FY2021$8.80 to $9.20$9.09
FY2022$9.60 to $10.00$9.34
FY2023$9.85 to $10.15$10.60
FY2024$11.70 to $12.00$12.19
FY2025$13.45 to $13.70$13.63
FY2026 forecast
Adjusted EPS $14.90 to $15.10, given 29 January 2026. Its result comes with the fourth-quarter results for FY2026.
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Adjusted EPS
The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020FY2021FY2022 †FY2023 †FY2024FY2025TTM
Operating cash flow1,0281,1761,4611,5471,4341,6571,8861,7829811,9151,5592,6102,1913,2773,2632,6243,7114,2425,0445,446
Capital expenditure188155131182226210195233270490598572649487525588575755761873
Free cash flow8411,0211,3301,3651,2081,4471,6911,5497111,4259612,0381,5422,7902,7382,0363,1363,4874,2834,573
Free cash flow margin14.0%15.2%19.8%18.7%14.5%16.7%18.7%16.0%7.1%12.6%7.7%15.0%10.4%19.4%16.0%11.0%15.3%15.4%17.1%17.4%
Cash from investing-1,178310-1,328-796-2,135-736-2,217-1,8781,956-4,191-1,613-2,857-1,455-4,701-859-2,924-962-3,000-4,866-1,316
Cash from financing13.6-1,046-193410-161-449300629-1,2232,258-7941,3293.0-11.0-2,365-749-1,594-525113-4,091
Depreciation and amortisation1781953854104814865115865907528599661,0441,0761,2721,2781,3411,4261,5701,614
Share-based compensation61.365.562.069.075.075.076.077.086.097.0113119127142171168205229243256
Buybacks0.01,0000.042662210831710070013.02303003070.00.0n/an/an/an/an/a
Dividends paid89.71361982382793244014625215686367037788639501,0511,1391,2191,2841,333
Dividend per share$0.33$0.40$0.25$0.63$0.75$0.90$1.10$1.26$1.42$1.56n/an/an/an/an/an/an/an/an/a$3.52
Diluted shares, weightedn/a414m399m400m390m383m382m383m381m378m380m380m380m380m382m382m384m386m386m385m
Shares outstanding at period endn/a396m398m391m381m380m378m378m373m375m374mn/an/an/an/an/an/an/an/a381m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019 †FY2020FY2021FY2022 †FY2023 †FY2024FY2025TTM
Funded by
Shareholders' equity5,3785,4076,5957,1747,6838,5979,0478,5958,5119,5509,96611,73012,80713,08414,87716,61618,59320,63422,42023,457
Non-controlling interestn/an/an/an/an/an/an/an/an/a0.014.0n/an/an/an/an/an/an/an/an/a
Debtn/an/a18.01,0221,7681,7622,7643,9733,9986,9147,2229,85911,09013,99112,47913,04812,99513,59715,85914,930
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a301325310357356379348343
Other liabilitiesn/a2,1972,4582,4632,6952,8473,5884,6903,7383,9714,9955,6405,9696,9306,9656,8637,9688,3619,2178,517
Total liabilities and equityn/a7,6039,07110,65812,14613,20615,39917,25816,24720,43522,19727,22930,16734,33034,63136,88439,91242,97147,84447,247
Owned
Fixed assetsn/a9649487988889481,0811,0981,1991,5691,9752,2912,5672,7522,8332,9703,2153,4483,8764,054
Goodwilln/a5689571,0722,0722,1423,8444,1864,1366,3567,1688,5639,06912,77812,91814,88015,24315,85519,29119,326
Intangible assetsn/a3686357031,4421,4241,9892,0181,7943,5083,4774,1634,2275,5544,8404,8854,5934,3955,6815,542
Investmentsn/a1,4942,2962,6222,5132,8902,6413,20570068.025183.088.081.075.084.082.091.089.00.0
Cash and equivalents2907016591,7589051,3951,3391,7953,3793,3162,5423,6164,3372,9432,9441,8442,9713,6524,0113,271
Receivablesn/a1,1301,1471,2521,4171,4301,5181,5721,6621,9672,1982,3322,8932,7013,0223,5653,7653,9874,0393,693
Inventoryn/a9539431,0571,2831,2651,4221,5881,6392,0302,4652,9552,9803,4943,3143,9954,8434,7745,3105,747
Other assetsn/a1,4261,4871,3961,6261,7121,5651,7961,7381,6212,1213,2264,0064,0274,6854,6615,2006,7695,5475,614
Total assetsn/a7,6039,07110,65812,14613,20615,39917,25816,24720,43522,19727,22930,16734,33034,63136,88439,91242,97147,84447,247
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded9.7%11.8%10.8%7.9%
Profit growth, compounded8.5%15.2%11.2%23.1%
Return on equity, average16.0%14.7%15.3%14.5%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Stryker's revenue in fiscal 2025?

Stryker (SYK) reported revenue of $25.1 billion for fiscal 2025, the year ended 31 December 2025, up 11.2% on the year before.

How much did Stryker earn in fiscal 2025?

Net income was $3.2 billion for fiscal 2025, and diluted earnings per share $8.40.

What is Stryker's P/E ratio?

At the close of 6 November 2026, Stryker traded at 34.7 times its earnings over the twelve months to 30 September 2026.

What is Stryker's market cap?

The market cap of Stryker was $124.0 billion at the close of 6 November 2026.

Does Stryker pay a dividend?

Yes. Stryker declared $3.52 a share in dividends over the four quarters to 30 September 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
70 companies share its SEC industry code (Surgical & Medical Instruments & Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on SYK

Dividends$3.52 a share over the four quarters to 30 September 2026, a 1.08% yield
Filings21 in twelve months: 13 current reports (8-K), about 5 regulation FD disclosure; 4 results of operations; 3 officer or director change; 2 other events; 1 shareholder vote
Planned insider sales10 Form 144 notices in twelve months, $406.2 million; latest 5 November 2026
Options tapeput/call 0.51 by open interest at the 6 November 2026 close; the straddle prices a 5.6% move to 20 November 2026
13F holders2,272 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading57 sales and 5 purchases on Form 4 in twelve months
Congress3 House trades disclosed in six months
Short interest5.7 million shares short, 2.39 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202630 October 2026EDGAR
10-Q30 June 202631 July 2026EDGAR
10-Q31 March 202611 May 2026EDGAR
10-K31 December 202511 February 2026EDGAR
10-Q30 September 202531 October 2025EDGAR
10-Q30 June 20251 August 2025EDGAR
10-Q31 March 20252 May 2025EDGAR
10-K31 December 202412 February 2025EDGAR
10-Q30 September 202430 October 2024EDGAR
10-Q30 June 202431 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.